{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:11:01Z","timestamp":1755216661468,"version":"3.43.0"},"reference-count":38,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"2","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":" Background<\/jats:title> Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment options is not feasible. Thus, network meta-analyses play an important role in allowing health-care decision makers to compare the effectiveness of treatment options.<\/jats:p> <\/jats:sec> Objectives<\/jats:title> A Bayesian network meta-analysis (NMA) was developed from studies identified from a systematic literature review (SLR) to evaluate the efficacy of once weekly oral selinexor with once weekly bortezomib and low-dose dexamethasone (XVd) relative to other therapies in previously treated MM.<\/jats:p> <\/jats:sec> Methods<\/jats:title> Ovid was systematically searched for phase 2-3 randomized clinical trials (RCTs) in MM that assessed progression-free survival (PFS), overall survival (OS) and overall response rates (ORR). Two population subsets were assessed: second-line patients (2L) and third-line or greater patients (3L+). Base case results compared all regimens against twice weekly bortezomib and dexamethasone (Vd) as the anchored comparator regimen.<\/jats:p> <\/jats:sec> Results<\/jats:title> Forty-seven RCTs met inclusion. For 2L PFS, OS and ORR, XVd had, on average, out of all iterations, the 6th (out of 21), 4th (out of 15), and 5th (out of 20) best result, respectively, versus Vd. For 3L+ PFS, OS and ORR, XVd had the 12th (out of 24), 11th (out of 22), and 8th (out of 25) best result, respectively, versus Vd. There was no statistically significant difference between XVd and other top-ranking therapies for PFS, OS, and ORR in either 2L and 3L+ except for daratumumab\/bortezomib\/dexamethasone [DVd], which was favorable versus XVd (2L PFS only).<\/jats:p> <\/jats:sec> Discussion<\/jats:title> Results for XVd were more favorable in 2L, having a higher probability of being a top 5 regimen, compared with 3L+ therapies based on the reported clinical trial results. However, in typical clinical practice, most triplet regimens have been modified using weekly bortezomib dosing, raising questions about the actual efficacy of these regimens versus the reported results using twice weekly bortezomib dosing.<\/jats:p> <\/jats:sec> Conclusions<\/jats:title> The addition of XVd, which was designed with once weekly bortezomib dosing, to the treatment landscape for previously treated MM provides a regimen that may potentially be noninferior to the other top 5 regimens in both 2L and 3L+ settings and is associated with less peripheral neuropathy.<\/jats:p> <\/jats:sec>","DOI":"10.36469\/001c.27080","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T08:58:59Z","timestamp":1629881939000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":1,"title":["Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma"],"prefix":"10.36469","volume":"8","author":[{"given":"Michael","family":"Dolph","sequence":"first","affiliation":[{"name":"Purple Squirrel Economics, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Purple Squirrel Economics, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne M","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyee","family":"Leong","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22273","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: A comprehensive overview","volume":"33","author":"Abdul Hamid Bazarbachi","year":"2019","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"ref2","first-page":"360","article-title":"Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"2013","author":"J.R. Mikhael","journal-title":"Mayo Clin Proc"},{"issue":"suppl_4","key":"ref3","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"P. Moreau","year":"2017","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"journal-title":"Karyopharm Therapeutics","article-title":"XPOVIO (selinexor). Prescribing Information","year":"2021","key":"ref4"},{"issue":"34","key":"ref5","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"A.R.A. Razak","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jha2.122","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"C. Gasparetto","year":"2021"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/pharmpract.2017.01.943","article-title":"Network meta-analysis: A technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Fernanda S. Tonin","year":"2017","journal-title":"Pharmacy Practice","ISSN":"https:\/\/id.crossref.org\/issn\/1885-642X","issn-type":"print"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"f3675","DOI":"10.1136\/bmj.f3675","article-title":"Analysis of the systematic reviews process in reports of network meta-analyses: Methodological systematic review","volume":"347","author":"A. Bafeta","year":"2013","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/1756-1833","issn-type":"print"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"g1741","DOI":"10.1136\/bmj.g1741","article-title":"Reporting of results from network meta-analyses: Methodological systematic review","volume":"348","author":"A. Bafeta","year":"2014","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/1756-1833","issn-type":"print"},{"article-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019","author":"J.T.P. Higgins","key":"ref10"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Shaji K. Kumar","year":"2017","journal-title":"Nature Reviews Disease Primers","ISSN":"https:\/\/id.crossref.org\/issn\/2056-676X","issn-type":"print"},{"year":"2013","key":"ref12","article-title":"Guide to the Methods of Technology Appraisal"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3324\/haematol.2014.112037","article-title":"Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma","volume":"100","author":"M.A. Dimopoulos","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"ref14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"M.A. Dimopoulos","year":"2021","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"4","key":"ref15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: Guidelines from the Mayo stratification for myeloma and risk-adapted therapy","volume":"92","author":"David Dingli","year":"2017","journal-title":"Mayo Clinic Proceedings","ISSN":"https:\/\/id.crossref.org\/issn\/0025-6196","issn-type":"print"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1586\/17474086.2014.899144","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"7","author":"Sebastian Grosicki","year":"2014","journal-title":"Expert Review of Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/1747-4086","issn-type":"print"},{"issue":"6","key":"ref17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/phar.2267","article-title":"Efficacy and safety of once-weekly versus twice-weekly bortezomib in patients with hematologic malignancies: a meta-analysis with trial sequential analysis","volume":"39","author":"Bin Hu","year":"2019","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Meletios A Dimopoulos","year":"2016","journal-title":"The Lancet Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"},{"issue":"8","key":"ref19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/nejmoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Antonio Palumbo","year":"2016","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"23","key":"ref20","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Sara Bringhen","year":"2010","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"article-title":"A Phase 1b\/2 Study of selinexor, carfilzomib, and dexamethasone (SKd) in relapsed\/refractory multiple myeloma (RRMM)","year":"2019","author":"C. Gasparetto","key":"ref21"},{"key":"ref22","article-title":"National Institutes of Health. Surveillance, Epidemiology, and End Results Program. Multiple Myeloma incidence rates per 100 000, SEER 13"},{"issue":"10262","key":"ref23","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Sebastian Grosicki","year":"2020","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"2","key":"ref24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.str.2014.11.019","article-title":"Bortezomib-resistant mutant proteasomes: Structural and biochemical evaluation with carfilzomib and ONX 0914","volume":"23","author":"Eva M. Huber","year":"2015","journal-title":"Structure","ISSN":"https:\/\/id.crossref.org\/issn\/0969-2126","issn-type":"print"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10428194.2018.1466392","article-title":"A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: A network meta-analysis","volume":"60","author":"K. Weisel","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2040620720930629","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Joshua Richter","year":"2020","journal-title":"Therapeutic Advances in Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/2040-6207","issn-type":"print"},{"article-title":"Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma","year":"2019","author":"C.I. Chen","key":"ref27"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00277-021-04404-3","article-title":"Treatment of relapsed\/refractory multiple myeloma in the bortezomib and lenalidomide era: A systematic review and network meta-analysis","volume":"100","author":"Leonardo Javier Arcuri","year":"2021","journal-title":"Annals of Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/0939-5555","issn-type":"print"},{"issue":"12","key":"ref29","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/jco.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"Chrissy H.Y. van Beurden-Tan","year":"2017","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"3","key":"ref30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clinthera.2018.01.014","article-title":"Comparative efficacy of treatments for previously treated multiple myeloma: A systematic literature review and network meta-analysis","volume":"40","author":"Eric M. Maiese","year":"2018","journal-title":"Clinical Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0149-2918","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8018","article-title":"Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM)","author":"D. White","year":"2021"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Rebecca L. Siegel","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians","ISSN":"https:\/\/id.crossref.org\/issn\/0007-9235","issn-type":"print"},{"journal-title":"American Cancer Society","key":"ref33","article-title":"Cancer Facts & Figures 2020"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Nicolas Despi\u00e9gel","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/2152-2650","issn-type":"print"},{"issue":"11","key":"ref35","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","article-title":"Patient-reported factors in treatment satisfaction in patients with relapsed\/ refractory Multiple Myeloma (RRMM)","volume":"24","author":"Ajai Chari","year":"2019","journal-title":"The Oncologist","ISSN":"https:\/\/id.crossref.org\/issn\/1083-7159","issn-type":"print"},{"key":"ref36","article-title":"NCCN guidelines: Multiple myeloma, version 7.2021","author":"S.K. Kumar","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network. Published April"},{"issue":"11","key":"ref37","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with\u2265 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Saad Usmani","year":"2016","journal-title":"The Oncologist","ISSN":"https:\/\/id.crossref.org\/issn\/1083-7159","issn-type":"print"},{"issue":"1","key":"ref38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40487-015-0009-4","article-title":"Evolving paradigms in the management of multiple myeloma: Novel agents and targeted therapies","volume":"3","author":"Jeremy T. Larsen","year":"2015","journal-title":"Rare Cancers and Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2195-6014","issn-type":"print"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/27080-network-meta-analysis-of-once-weekly-selinexor-bortezomib-dexamethasone-in-previously-treated-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:29:06Z","timestamp":1754328546000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/27080-network-meta-analysis-of-once-weekly-selinexor-bortezomib-dexamethasone-in-previously-treated-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.27080","relation":{},"ISSN":["2327-2236"],"issn-type":[{"type":"electronic","value":"2327-2236"}],"subject":[],"published":{"date-parts":[[2021,8,25]]}}}